<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019616</url>
  </required_header>
  <id_info>
    <org_study_id>D09050703570904</org_study_id>
    <nct_id>NCT01019616</nct_id>
  </id_info>
  <brief_title>Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy</brief_title>
  <official_title>A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tao OUYANG</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Science &amp; Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled&#xD;
      study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can&#xD;
      increase distant disease free survival(DDFS) in operable patients non-response to primary&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">March 4, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant disease-free survival (DDFS)</measure>
    <time_frame>3 years after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Primary Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel/anthracycline</intervention_name>
    <description>standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Alternative Non-cross-resistant Adjuvant Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients, age ≦65 years&#xD;
&#xD;
          -  Biopsy proven lymph node positive, estrogen receptor- positive primary breast cancer&#xD;
&#xD;
          -  Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard&#xD;
             regimen(containing anthracycline or paclitaxel)&#xD;
&#xD;
          -  Must have undergone surgery to remove the primary tumor by either a mastectomy or&#xD;
             enlarged local excision&#xD;
&#xD;
          -  Postoperative residual positive lymph nodes or G1/G2/G3 of Miller &amp; Payne Grading&#xD;
             System&#xD;
&#xD;
          -  Adequate recovery from recent surgery&#xD;
&#xD;
          -  No history of other malignancies&#xD;
&#xD;
          -  No currently uncontrolled diseased or active infection&#xD;
&#xD;
          -  Not pregnant or breast feeding, and on appropriate birth control if of child-bearing&#xD;
             potential&#xD;
&#xD;
          -  Adequate cardiovascular function reserve with a myocardial infarction within the past&#xD;
             six month&#xD;
&#xD;
          -  Adequate hematologic function with:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1500/mm3&#xD;
&#xD;
               2. Platelets ≥100,000/ mm3&#xD;
&#xD;
               3. Hemoglobin ≥10 g/dL&#xD;
&#xD;
          -  Adequate hepatic and renal function with:&#xD;
&#xD;
               1. Serum bilirubin ≤1.5×UNL&#xD;
&#xD;
               2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤2.5 x ULN. (≤5 x ULN is&#xD;
                  acceptable in the setting of hepatic metastasis)&#xD;
&#xD;
               3. BUN between 1.7 and 8.3 mmol/L&#xD;
&#xD;
               4. Cr between 40 and 110 umol/L&#xD;
&#xD;
          -  Knowledge of the investigational nature of the study and Ability to give informed&#xD;
             consent&#xD;
&#xD;
          -  Ability and willingness to comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected distant metastases&#xD;
&#xD;
          -  Concurrent malignancy or history of other malignancy&#xD;
&#xD;
          -  Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months,&#xD;
             arrhythmia, unstable diabetes, hypercalcemia) or active infection&#xD;
&#xD;
          -  Geographical, social, or psychological problems that would compromise study compliance&#xD;
&#xD;
          -  Known or suspected hypersensitivity to anthracycline or paclitaxel&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Ouyang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital Breast Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>307 Hospital of Pla</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital Breast Center</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institution and Hospital.Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People'S Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Tao OUYANG</investigator_full_name>
    <investigator_title>Chairman of Breast Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

